• br HER proto oncogene The erbB gene located

  2021-10-26

  

  HER2 proto-oncogene The erbB2 gene, located on the short arm of chromosome 17, was discovered and cloned in 1983 (Fig. 1) (Sato et al., 1983). The product of this gene, HER2, is a transmembrane glycoprotein of 185 KDa that consists of three main domains: an extracellular, a transmembrane and an i

• Several classes of small molecules that modulate CDK activit

  2021-10-26

  

  Several classes of small molecules that modulate CDK8 activity have been reported in the patent literature (Fig. 1). A quinazoline derivative, Senexin B (SNX2-1–165, 1), showed CDK8 enzyme inhibitory activity with an IC50 value of 24–50 nM in different assay, and displayed potent, selective enzymati

• Finally we find that in

  2021-10-26

  

  Finally, we find that in the absence of Aurora B, Sgo1 is delocalized from centromeres and found along chromosome arms, as reported after depletion of Bub1 (Kitajima et al., 2005, Riedel et al., 2006). The increased arm cohesion observed in the absence of Aurora B activity is dependent on the presen

• WYE-132 synthesis br Materials and methods br

  2021-10-26

  

  Materials and methods Results Discussion Early studies in the mid 1980s tentatively identified cCMP in tissues using fast atom bombardment MS [3], [4], but specificity and sensitivity of the method are insufficient for unequivocal identification as compared to modern MS analytical methods.

• GSK is inhibited by serine phosphorylation at

  2021-10-26

  

  GSK-3 is inhibited by serine glatiramer acetate at a residue its N-terminus (Ser 9 in GSK-3β and Ser 21 in GSK-3α) [52], [53], [54]. This raised the possibility that the N-terminal tail may function as a pseudo-substrate by mimicking the pre-phosphorylated substrate. The interaction mode of the pseu

• A few research articles described that

  2021-10-26

  

  A few research articles described that PLGA could alone improve physiological activities in certain illnesses by exerting therapeutic effects. These reported therapeutic activities of PLGA can be appended to the hydrolysis products of PLGA lactate, glycolate, and H+. We will recapitulate their respe

• APETx2 Based on these findings we set out to

  2021-10-26

  

  Based on these findings, we set out to identify GPR109A agonists capable of biasing the receptor's signaling towards the functional anti-lipolytic and presumed therapeutic response, and away from the flushing side-effect pathways. Indeed, using recombinantly expressed GPR109A, two classes of compoun

• br Acknowledgements This research was funded by

  2021-10-26

  

  Acknowledgements This research was funded by Ministry of Education Malaysia (MOE), and supported by the Department of Nutrition, Exercise & Sports, Department of Drug Design, University of Copenhagen, Denmark and Universiti Malaysia Pahang (UMP), Malaysia. HPLC equipment used for high-resolution

• br Conclusions We have shown that despite the development of

  2021-10-26

  

  Conclusions We have shown that despite the development of severe insulin intolerance and marked alterations in whole body substrate oxidation that Gcgr−/− mice are protected against olanzapine-induced hyperglycemia. Our data provides evidence that this protective effect is likely due in large par

• br Conflict of interest br Transparency document br Acknowle

  2021-10-26

  

  Conflict of interest Transparency document Acknowledgements We acknowledge our funding sources from the American Heart Association (13EIA4480016) and the National Institute of Health/National Heart, Lung, and Blood Institute (RO1 HL094414). We are very grateful to Dr. Shaohua Xiao and Dr. S

• A way to identify what subunit interfaces contribute to the

  2021-10-25

  

  A way to identify what subunit interfaces contribute to the pharmacology of agents is to utilise binary GABAARs as tool receptors to ascertain possible binding sites for particular ligands. These receptors can help identify subunits and subunit interfaces that contribute to receptor pharmacology. In

• br STAR Methods br Acknowledgments We would

  2021-10-25

  

  STAR★Methods Acknowledgments We would like to thank V. Gladyshev (Harvard), H. Kornblum (UCLA), L. Greene (Columbia), and J. Baraban (Johns Hopkins) for constructive comments to the project and manuscript. We thank L. Gross and A. Kumar for assistance with editing. We thank L.M. Gerber and Z.

• br Site of expression FASTK is expressed in

  2021-10-25

  

  Site of expression FASTK is expressed in various parts of human body including heart, skeletal muscle, brain, placenta, lung, liver, kidney pancreas (Ota et al., 2004) and many other organs (Fig. 1). It has been reported that FASTK is highly expressed in pancreatic tumors, where it is involved in

• Some studies using RNAi have recently been

  2021-10-25

  

  Some studies using RNAi have recently been invalidated by CRISPR/Cas9 [25] due to significant off-target effects of RNAi [26]. In this study, we have used both RNAi and CRISPR/Cas9 techniques and have observed consistent and similar phenotypes thus; knockdown or knockout of PATZ1 resulted in reducti

• In conclusions it is hypothesized

  2021-10-25

  

  In conclusions, it is hypothesized that caffeine administration could lead to an increase in histamine neuronal activation or release of histamine [38] to induced locomotor stimulation via H1 receptor activation. In addition, the present study also propose that the spaced administration of caffeine

15640 records 553/1043 page Previous Next First page 上5页 551552553554555 下5页 Last page